SGLT2 inhibitor
SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit
Medical uses
The 2022
A
A meta-analysis including 13 cardiovascular outcome trials found that SGLT-2 inhibitors reduce the risk for three-point
Two reviews have concluded that SGLT2 inhibitors benefit patients with atherosclerotic major adverse cardiovascular events (MACE).[10][11] One of those studies defined MACE as the composite of myocardial infarction, stroke, or cardiovascular death.[10]
Adverse effects
Genital infections seem to be the most common
In May 2015, the
In September 2015, the FDA issued a warning related to canagliflozin (Invokana) and canagliflozin/metformin (Invokamet) due to decreased bone mineral density and therefore increased risk of bone fractures. Using gliflozins in combination therapy with metformin can lower the risk of hypoglycemia compared to other type 2 diabetes treatments such as sulfonylureas and insulin.[12]
Increased risk of lower
In August 2018, the FDA issued a warning of an increased risk of Fournier gangrene in patients using SGLT2 inhibitors.[18] The absolute risk is considered very low.[19]
In the FDA Adverse Event Reporting System an increase was reported in events of acute kidney injury associated with SGLT2 inhibitors,[20][21] though data from clinical trials actually showed a reduction in such events with SGLT-2 treatment.[22]
Interactions
Interactions are important for SGLT2 inhibitors because most people with type 2 diabetes are taking many other medications. Gliflozins appear to increase the diuretic effect of
Members
These are the known members of the gliflozin class:
- Bexagliflozin was approved in the United States under the brand name Brenzavvy in January 2023.[25]
- Canagliflozin was the first SGLT2 inhibitor to be approved for use in the United States. It was approved in March 2013, under the brand name Invokana and it was also marketed throughout the EU under the same name.[26][27]
- Dapagliflozin, approved under the name Forxiga, was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere.[28] It was approved for use in the United States under the brand name Farxiga by the FDA in January 2014.[29] It was the first oral treatment, in combination with insulin, to treat type 1 diabetes in the UK and EU.
- Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim.[30] Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition.[1] This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death.[31]
- Ertugliflozin was approved in the United States under the brand name Steglatro in December 2017.[32]
- Ipragliflozin, produced by the Japanese company Astellas Pharma Inc. under the brand name Suglat, approved in Japan January 2014.[33][34]
- Luseogliflozin, developed by Taisho Pharmaceutical, was approved in Japan in March 2014 under the brand name Lusefi.[35]
- Remogliflozin etabonate was commercially launched first in India by Glenmark in May 2019.
- Sergliflozin etabonate discontinued after Phase II trials.[36]
- Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the FDA in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.[37][38]
- Tofogliflozin, developed by Sanofi and Kowa Pharmaceutical, was approved in Japan in March 2014, under the brand names Apleway and Deberza.[39]
- Henagliflozin, selective SGLT2 inhibitor. Approved in China.
- Janagliflozin.
- Mizagliflozin
- Velagliflozin Proline hydrate
- Enavogliflozin
Mechanism of action
Sodium Glucose cotransporters (SGLTs) are proteins that occur primarily in the kidneys and play an important role in maintaining glucose balance in the blood.
The mechanism of action on a cellular level is not well understood. Work is underway to define this mechanism as a prodiuretic with great promise. However, it has been shown that binding of different sugars to the glucose site affects the orientation of the aglycone in the access vestibule. So when the aglycone binds it affects the entire inhibitor. Together these mechanisms lead to a synergistic interaction. Therefore, variations in the structure of both the sugar and the aglycone are crucial for the pharmacophore of SGLT inhibitors.[43]
Dapagliflozin is an example of an SGLT-2 inhibitor, it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying
SGLT | Expressed in human tissues |
---|---|
SGLT1 | Intestine, trachea, kidney, heart, brain, testis, prostate |
SGLT2 | Kidney, brain, liver, thyroid, muscle, heart |
Ratios of activity between SGLT1 and SGLT2 may be helpful in defining expression.
Pharmacology
The
Name of drug | Bioavailability | Protein binding | tmax (hours) | t1/2 (hours) | Cmax | SGLT2 selectivity over SGLT1 |
---|---|---|---|---|---|---|
Canagliflozin | 65% (300 mg dose) | 99% | 1–2 | 10.6 (100 mg dose); 13.1 (300 mg dose) | 1096 ng/mL (100 mg dose); 3480 ng/mL (300 mg dose) | 250 fold |
Dapagliflozin | 78% | 91% | 1–1.5 | 12.9 | 79.6 ng/mL (5 mg dose); 165.0 ng/mL (10 mg dose) | 1200 fold |
Empagliflozin | 90–97% (mice); 89% (dogs); 31% (rats) | 86.20% | 1.5 | 13.2 (10 mg dose); 13.3h (25 mg dose) | 259nmol/L (10 mg dose); 687nmol/L (25 mg dose) | 2500 fold |
Ertugliflozin | 70-90% | 95% | 0.5-1.5 | 11-17 | 268 ng/mL (15 mg dose) | 2000 fold |
Ipragliflozin (50 mg) | 90% | 96.30% | 1 | 15–16 (50 mg dose) | 975 ng/mL | 360 fold |
Luseogliflozin | 35.3% (male rats); 58.2% (female rats); 92.7% (male dogs) | 96.0–96.3% | 0.625±0.354 | 9.24±0.928 | 119±27.0 ng/mL | 1650 fold |
Tofogliflozin (10 mg) | 97.50% | 83% | 0.75 | 6.8 | 489 ng/mL | 2900 fold |
- Cmax: Maximum serum concentration that drug achieves in body after the drug has been administered
- tmax: Time to achieve maximum plasma concentration
- t1/2: Biological half-life
In studies that were made on healthy people and people with type 2 diabetes, who were given dapagliflozin in either single ascending dose (SAD) or multiple ascending dose (MAD) showed results that confirmed a
Dapagliflozin disposition is not evidently affected by BMI or
Some studies found that dapagliflozin is associated with a decrease in body weight which is statistically superior compared to placebo or other active comparators.[50][44] It is primarily associated with caloric rather than fluid loss.[50][44]
In contrast with other
Structure-activity relationship
The
The most common gliflozins are dapagliflozin, empagliflozin and canagliflozin. The differences in the structures is relatively small. The general structure includes a glucose sugar with an
The synthesis of Gliflozins involves three general steps. The first one is the construction of the aryl substituent, the next one is the introduction of the aryl moiety onto the sugar or glucosylation of the aryl substituent and the last one the deprotection and modification of the arylated anomeric center of the sugar.[52]
Phlorizin was the first type of gliflozin and it was non-selective against SGLT2/SGLT1. It is a natural O-aryl glycoside composed of a d-glucose and an aromatic ketone.[53] However Phlorizin is very unstable, it is rapidly degraded by glucosidases in the small intestines, so it can not be used as an oral administration medication to treat diabetes. Structural modifications have been made to overcome this instability problem. The most efficient way was to conjugate aryl moiety with glucose moiety since C-glucosides are more stable in the small intestines than O-glucoside derivatives (C-C bond instead of C-O-C bond).[54]
In the sugar analogues of dapagliflozin, the β-C series are more active than α-C series so it is critical that the β-configuration is at C-1 for the inhibitory activity.[55] Both dapagliflozin and empagliflozin contain a chlorine (Cl) atom in their chemical structure. Cl is a halogen and it has a high electronegativity. This electronegativity withdraws electrons off the bonds and therefore it reduces the metabolism. The Cl atom also reduces the IC50 value of the medication so the medication has better activity. The carbon-fluorine bond (C-F) has also has a very low electron density.[55]
For example, in the chemical structure of canagliflozin a fluorine atom is connected to an aromatic ring then the compound is more stable and the metabolism of the compound is reduced. Empagliflozin contains a tetrahydrofuran ring but not canagliflozin nor dapagliflozin.[56]
In the development of gliflozins the distal ring contains a thiophene ring instead of an aromatic ring. However the final chemical structures of the marketing gliflozins does not contain this thiophene ring.[57]
History
Research
SGLT2 inhibitors increase circulating ketone body concentrations.[58] The cardioprotective effects of SGLT2 inhibitors have been attributed to the elevated ketone levels.[59]
Gliflozins have been posited to exhibit protective effects on the heart, liver, kidneys, anti‐hyperlipidemic, anti‐atherosclerotic, anti‐obesity, anti‐neoplastic effects in in vitro, pre‐clinical, and clinical studies. Pleiotropic effects of this class have been attributed to a variety of its pharmacodynamic actions such as natriuresis, hemoconcentration, deactivation of renin-angiotensin-aldosterone system, ketone body formation, alterations in energy homeostasis, glycosuria, lipolysis, anti‐inflammatory, and antioxidative actions.[60][3]
SGLT2 inhibitors have shown beneficial effects on liver function in clinical trials on individuals with
References
- ^ PMID 26586935.
- S2CID 3557967.
- ^ PMID 32021362.
- S2CID 9350259.
- PMID 25365416.
- ^ "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022". diabetesjournals.org. Retrieved 23 September 2022.
- PMID 29677303.
- S2CID 226285893.
- ^ PMID 37381019.
- ^ S2CID 53277899.
- PMID 34497814.
- ^ PMID 27898586.
- S2CID 4091595.
- PMID 29529345.
- ^ a b "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration. 19 March 2020. Retrieved 6 June 2020. This article incorporates text from this source, which is in the public domain.
- S2CID 3873882.
- ^ "SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information". European Medicines Agency. 4 May 2017.
- ^ "FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes". www.fda.gov. Center for Drug Evaluation and Research. 7 September 2018. p. Drug Safety and Availability. Retrieved 16 April 2019.
- S2CID 54471240.
- ^ "FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)". U.S. Food and Drug Administration (FDA). 9 February 2019.
- PMID 29174031.
- S2CID 202003028.
- ^ BNF 73. Tavistock Square, London: BMJ Group. March–September 2017.
- S2CID 5228432.
- ^ "Novel Drug Approvals for 2023". Food and Drug Administration (FDA). U.S. Food and Drug Administration. 20 January 2023.
- ^ "Drug Approval Package: Invokana (canagliflozin) Tablets NDA #204042". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 5 May 2020.
- ^ "Invokana EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 1 October 2018.
- ^ "Forxiga EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 17 February 2020.
- ^ "Drug Approval Package: Farxiga (dapagliflozin) Tablets NDA #202293". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 5 May 2020.
- ^ "FDA approves Jardiance (empagliflozin) tablets for adults with type 2 diabetes". Boehringer Ingelheim / Eli Lilly and Company. 1 August 2014. Archived from the original on 5 November 2014. Retrieved 5 November 2014.
- ^ "FDA Advisory Committee recommends approval of Jardiance (empagliflozin) for cardiovascular indication in 12-11 vote". Yahoo! Finance. 28 June 2016. Retrieved 10 August 2016.
- ^ "Steglatro (ertugliflozin), Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) Tablets". U.S. Food and Drug Administration (FDA). 5 March 2018. Retrieved 6 May 2020.
- ^ "Approval of Suglat® Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan". 17 January 2014. Archived from the original on 23 September 2015. Retrieved 19 May 2015.
- S2CID 19837125.
- S2CID 1770988.
- PMID 30151080.
- ^ "Inpefa- sotagliflozin tablet". DailyMed. 5 June 2023. Archived from the original on 26 June 2023. Retrieved 25 June 2023.
- ^ "Once-Daily Inpefa Approved for Treating Heart Failure". www.uspharmacist.com. Retrieved 25 December 2023.
- S2CID 37021884.
- PMID 26246672.
- ^ S2CID 207264502.
- ^ PMID 21398124.
- PMID 21940664.
- ^ S2CID 195682848.
- ^ "Jardiance". drugs.com. Retrieved 31 October 2014.
- ^ "Farxiga". drugs.com. Retrieved 31 October 2014.
- ^ "Invokana". drugs.com. Retrieved 31 October 2014.
- PMID 27531551.
- PMID 22262072.
- ^ PMID 23910664.
- ^ S2CID 221540765.
- ^ LARSON GL (March–April 2015). "The synthesis of gliflozins". Chimica Oggi - Chemistry Today. 33 (2): 37–40. Archived from the original on 30 September 2018. Retrieved 1 October 2018.
- PMID 32231437.
- .
- ^ PMID 28717146.
- ^ "7.5: Electron Affinities". Chemistry LibreTexts. 18 November 2014. Retrieved 30 September 2018.
- PMID 24900297.
- PMID 28178565.
- PMID 34879839.
- PMID 33964138.
- S2CID 248846797.
- PMID 35328527.
External links
- "FDA revises label of diabetes drug canagliflozin". U.S. Food and Drug Administration. 15 January 2016.
- "FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)". U.S. Food and Drug Administration. 18 May 2016.
- "FDA Drug Safety Communication: Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet); FDA to investigate". U.S. Food and Drug Administration. 9 May 2017.
- "Warning use metformin in certain patients with reduced kidney function". U.S. Food and Drug Administration. 14 November 2017.
- "Warning: infection of genital area with SGLT2 inhibitors for diabetes". U.S. Food and Drug Administration. 7 September 2018.